Lead Product(s) : EG110A
Therapeutic Area : Urology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : $20.2 million
Deal Type : Series A Financing
EG 427 Announces Final Series a Closing, Achieving €18 Million in Total Funds Raised
Details : The funding will be used to advance company's pipeline, culminating in the Investigational New Drug application filing for the first clinical study of its lead product, EG110A which targets the silencing of type-C sensory neuronsm and is being developed ...
Product Name : EG110A
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 13, 2023
Lead Product(s) : EG110A
Therapeutic Area : Urology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : $20.2 million
Deal Type : Series A Financing